Rituximab in primary Sjögren's syndrome: A ten-year journey

Lupus

Volumn 23, Issue 13, 2014, Pages 1337-1349

  Carubbi, F ^a   Alunno, A ^b   Cipriani, P ^a   Bartoloni, E ^b   Ciccia, F ^c   Triolo, G ^c   Gerli, R ^b   Giacomelli, R ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

^c UNIVERSITY OF PALERMO   (Italy)

Author keywords

B cells; biological therapies; Primary Sj gren's syndrome; rituximab

Indexed keywords

RITUXIMAB; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

AUTOIMMUNE DISEASE; B LYMPHOCYTE; BIOLOGICAL THERAPY; DISEASE SEVERITY; DRUG EFFICACY; EVIDENCE BASED MEDICINE; HUMAN; INFLAMMATION; LYMPHOID ORGAN; PATHOGENESIS; PRACTICE GUIDELINE; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SJOEGREN SYNDROME; TARGET ORGAN; DRUG EFFECTS; LYMPHOCYTE COUNT; SJOGREN'S SYNDROME;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; B-LYMPHOCYTES; HUMANS; IMMUNOLOGIC FACTORS; LYMPHOCYTE COUNT; SJOGREN'S SYNDROME;

EID: 84909643080     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203314546023     Document Type: Review

References (63)

1. Mavragani CP, Nezos A, Moutsopoulos HM. New advances in the classification, pathogenesis and treatment of Sjögren's syndrome. Curr Opin Rheumatol. 2013 ; 25: 623-629
2. Christodoulou MI, Kapsogeorgou EK, Moutsopoulos HM. Characteristics of the minor salivary gland infiltrates in Sjögren's syndrome. J Autoimmun. 2010 ; 34: 400-407
3. Sarigul M, Yazisiz V, Bassorgun CI, et al. The numbers of Foxp3 + Treg cells are positively correlated with higher grade of infiltration at the salivary glands in primary Sjögren's syndrome. Lupus. 2010 ; 19: 138-145
4. Alunno A, Bistoni O, Bartoloni E, et al. IL-17-producing CD4-CD8- T cells are expanded in the peripheral blood, infiltrate salivary glands and are resistant to corticosteroids in patients with primary Sjögren's syndrome. Ann Rheum Dis. 2013 ; 72: 286-292
5. Alunno A, Carubbi F, Bistoni O, et al. CD4-CD8- T-cells in primary Sjögren's syndrome: Association with the extent of glandular involvement. J Autoimmun. 2014 ; 51: 38-43
6. Nocturne G, Mariette X. Advances in understanding the pathogenesis of primary Sjögren's syndrome. Nat Rev Rheumatol. 2013 ; 9: 544-556
7. Ramos-Casals M, Tzioufas AG, Stone JH, et al. Treatment of primary Sjögren syndrome: A systematic review. JAMA. 2010 ; 304: 452-460
8. Ramos-Casals M, Brito-Zerón P, Sisó-Almirall A, Bosch X, Tzioufas AG. Topical and systemic medications for the treatment of primary Sjögren's syndrome. Nat Rev Rheumatol. 2012 ; 8: 399-411
9. Brito-Zerón P, Sisó-Almirall A, Bové A, Kostov BA, Bamos-Casals M. Primary Sjögren syndrome: An update on current pharmacotherapy options and future directions. Expert Opin Pharmacother. 2013 ; 14: 279-289
10. Fazaa A, Bourcier T, Chatelus E, et al. Classification criteria and treatment modalities in primary Sjögren's syndrome. Expert Rev Clin Immunol. 2014 ; 10: 543-551
11. Kroese FG, Abdulahad WH, Haacke E, Bos NA, Vissink A, Bootsma H. B-cell hyperactivity in primary Sjögren's syndrome. Expert Rev Clin Immunol. 2014 ; 10: 483-499
12. Carubbi F, Alunno A, Cipriani P, et al. Is minor salivary gland biopsy more than a diagnostic tool in primary Sjögren's syndrome? Association between clinical, histopathological, and molecular features: A retrospective study. Semin Arthritis Rheum. :
13. Anolik JH, Looney RJ, Lund FE. Insights into the heterogeneity of human B cells: Diverse functions, roles in autoimmunity, and use as therapeutic targets. Immunol Res. 2009 ; 45: 144-158
14. Tatouli IP, Tzioufas AG. Pathogenetic aspects of humoral autoimmunity in Sjögren's syndrome. Lupus. 2012 ; 21: 1151-1154
15. Voulgarelis M, Tzioufas AG. Pathogenetic mechanisms in the initiation and perpetuation of Sjögren's syndrome. Nat Rev Rheumatol. 2010 ; 6: 529-537
16. Quartuccio L, Isola M, Baldini C, et al. Biomarkers of lymphoma in Sjögren's syndrome and evaluation of the lymphoma risk in prelymphomatous conditions: Results of a multicenter study. J Autoimmun. 2014 ; 51: 75-80
17. Pescovitz MD. Rituximab, an anti-CD20 monoclonal antibody: History and mechanism of action. Am J Transplant. 2006 ; 6 (5 Pt 1). 859-866
18. Perosa F, Prete M, Racanelli V, Dammacco F. CD20-depleting therapy in autoimmune diseases: From basic research to the clinic. J Intern Med. 2010 ; 267: 260-277
19. Devauchelle-Pensec V, Pennec Y, Morvan J, et al. Improvement of Sjögren's syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum. 2007 ; 57: 310-317
20. Pijpe J, Meijer JM, Bootsma H, et al. Clinical and histologic evidence of salivary gland restoration supports the efficacy of rituximab treatment in Sjögren's syndrome. Arthritis Rheum. 2009 ; 60: 3251-3256
21. Pers JO, Devauchelle V, Daridon C, et al. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome. Arthritis Rheum. 2007 ; 56: 1464-1477
22. Mackay F, Schneider P. Cracking the BAFF code. Nat Rev Immunol. 2009 ; 9: 491-502
23. Lahiri A, Pochard P, Le Pottier L, et al. The complexity of the BAFF TNF-family members: Implications for autoimmunity. J Autoimmun. 2012 ; 39: 189-198
24. Wildenberg ME, van Helden-Meeuwsen CG, van de Merwe JP, Drexhage HA, Versnel MA. Systemic increase in type I interferon activity in Sjögren's syndrome: A putative role for plasmacytoid dendritic cells. Eur J Immunol. 2008 ; 38: 2024-2033
25. Youinou P, Pers JO. Disturbance of cytokine networks in Sjögren's syndrome. Arthritis Res Ther. 2011 ; 13: 227
26. Darce JR, Arendt BK, Wu X, Jelinek DF. Regulated expression of BAFF-binding receptors during human B cell differentiation. J Immunol. 2007 ; 179: 7276-7286
27. Abdulahad WH, Meijer JM, Kroese FG, et al. B cell reconstitution and T helper cell balance after rituximab treatment of active primary Sjögren's syndrome: A double-blind, placebo-controlled study. Arthritis Rheum. 2011 ; 63: 1116-1123
28. St Clair EW, Levesque MC, Prak ET, et al. Rituximab therapy for primary Sjögren's syndrome: An open-label clinical trial and mechanistic analysis. Arthritis Rheum. 2013 ; 65: 1097-1106
29. Hamza N, Bootsma H, Yuvaraj S, et al. Persistence of immunoglobulin-producing cells in parotid salivary glands of patients with primary Sjögren's syndrome after B cell depletion therapy. Ann Rheum Dis. 2012 ; 71: 1881-1887
30. Hershberg U, Meng W, Zhang B, et al. Persistence and selection of an expanded B cell clone in the setting of rituximab therapy for Sjögren's syndrome. Arthritis Res Ther. 2014 ; 16: R51
31. Pollard RP, Abdulahad WH, Vissink A, et al. Serum levels of BAFF, but not APRIL, are increased after rituximab treatment in patients with primary Sjögren's syndrome: Data from a placebo-controlled clinical trial. Ann Rheum Dis. 2013 ; 72: 146-148
32. Ciccia F, Guggino G, Rizzo A, et al. Rituximab modulates IL-17 expression in the salivary glands of patients with primary Sjögren's syndrome. Rheumatology (Oxford). 2014 ; 53: 1313-1320
33. Ciccia F, Giardina A, Rizzo A, et al. Rituximab modulates the expression of IL-22 in the salivary glands of patients with primary Sjögren's syndrome. Ann Rheum Dis. 2013 ; 72: 782-783
34. Pollard RP, Abdulahad WH, Bootsma H, et al. Predominantly proinflammatory cytokines decrease after B cell depletion therapy in patients with primary Sjögren's syndrome. Ann Rheum Dis. 2013 ; 72: 2028-2050
35. Sisto M, Lisi S, D'Amore M, Lofrumento DD. Rituximab-mediated Raf kinase inhibitor protein induction modulates NF-κB in Sjögren's syndrome. Immunology. :
36. Carubbi F, Cipriani P, Marrelli A, et al. Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: A prospective, multicenter, follow-up study. Arthritis Res Ther. 2013 ; 15: R172
37. Aloisi F, Pujol-Borrell R. Lymphoid neogenesis in chronic inflammatory diseases. Nat Rev Immunol. 2006 ; 6: 205-217
38. Pitzalis C, Jones GW, Bombardieri M, Jones SA. Ectopic lymphoid-like structures in infection, cancer and autoimmunity. Nat Rev Immunol. 2014 ; 14: 447-462
39. Hansen A, Reiter K, Ziprian T, et al. Dysregulation of chemokine receptor expression and function by B cells of patients with primary Sjögren's syndrome. Arthritis Rheum. 2005 ; 52: 2109-2119
40. Hansen A, Lipsky PE, Dörner T. B cells in Sjögren's syndrome: Indications for disturbed selection and differentiation in ectopic lymphoid tissue. Arthritis Res Ther. 2007 ; 9: 218
41. Pereira JP, Kelly LM, Cyster JG. Finding the right niche: B-cell migration in the early phases of T-dependent antibody responses. Int Immunol. 2010 ; 22: 413-419
42. Meijer JM, Pijpe J, Vissink A, Kallenberg CG, Bootsma H. Treatment of primary Sjögren's syndrome with rituximab: Extended follow-up, safety and efficacy of retreatment. Ann Rheum Dis. 2009 ; 68: 284-285
43. Gottenberg JE, Guillevin L, Lambotte O, et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis. 2005 ; 64: 913-920
44. Pijpe J, van Imhoff GW, Spijkervet FK, et al. Rituximab treatment in patients with primary Sjögren's syndrome: An open-label phase II study. Arthritis Rheum. 2005 ; 52: 2740-2750
45. Jousse-Joulin S, Devauchelle-Pensec V, Morvan J, et al. Ultrasound assessment of salivary glands in patients with primary Sjögren's syndrome treated with rituximab: Quantitative and Doppler waveform analysis. Biologics. 2007 ; 1: 311-319
46. Seror R, Sordet C, Guillevin L, et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome. Ann Rheum Dis. 2007 ; 66: 351-357
47. Galarza C, Valencia D, Tobón GJ, et al. Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases?. Clin Rev Allergy Immunol. 2008 ; 34: 124-128
48. Dass S, Bowman SJ, Vital EM, et al. Reduction of fatigue in Sjögren syndrome with rituximab: Results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis. 2008 ; 67: 1541-1544
49. Ramos-Casals M, García-Hernández FJ, de Ramón E, et al. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases. Clin Exp Rheumatol. 2010 ; 28: 468-476
50. Meijer JM, Meiners PM, Vissink A, et al. Effectiveness of rituximab treatment in primary Sjögren's syndrome: A randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010 ; 62: 960-968
51. Meiners PM, Arends S, Brouwer E, Spijkervet FK, Vissink A, Bootsma H. Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren's syndrome treated with rituximab. Ann Rheum Dis. 2012 ; 71: 1297-1302
52. Terrier B, Launay D, Kaplanski G, et al. Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: Data from the French Autoimmunity and Rituximab registry. Arthritis Care Res (Hoboken). 2010 ; 62: 1787-1795
53. Tony HP, Burmester G, Schulze-Koops H, et al. Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: Experience from a national registry (GRAID). Arthritis Res Ther. 2011 ; 13: R75
54. Mekinian A, Ravaud P, Larroche C, et al. Rituximab in central nervous system manifestations of patients with primary Sjögren's syndrome: Results from the AIR registry. Clin Exp Rheumatol. 2012 ; 30: 208-212
55. Mekinian A, Ravaud P, Hatron PY, et al. Efficacy of rituximab in primary Sjögren's syndrome with peripheral nervous system involvement: Results from the AIR registry. Ann Rheum Dis. 2012 ; 71: 84-87
56. Gottenberg JE, Cinquetti G, Larroche C, et al. Efficacy of rituximab in systemic manifestations of primary Sjögren's syndrome: Results in 78 patients of the AutoImmune and Rituximab registry. Ann Rheum Dis. 2013 ; 72: 1026-1031
57. Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, et al. Treatment of primary Sjögren syndrome with rituximab: A randomized trial. Ann Intern Med. 2014 ; 160: 233-242
58. Devauchelle-Pensec V, Morvan J, Rat AC, et al. Effects of rituximab therapy on quality of life in patients with primary Sjögren's syndrome. Clin Exp Rheumatol. 2011 ; 29: 6-12
59. Brown S, Navarro Coy N, Pitzalis C, et al. The TRACTISS protocol: A randomised double blind placebo controlled clinical trial of anti-B-cell therapy in patients with primary Sjögren's syndrome. BMC Musculoskelet Disord. 2014 ; 15: 21
60. Seror R, Theander E, Bootsma H, et al. Outcome measures for primary Sjögren's syndrome: A comprehensive review. J Autoimmun. 2014 ; 51: 51-56
61. Moerman RV, Arends S, Meiners PM, et al. EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomized controlled trial. Ann Rheum Dis. 2014 ; 73: 472-474
62. Seror R, Theander E, Brun JG, et al. Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI). Ann Rheum Dis. :
63. De Vita S, Quartuccio L, Salvin S, et al. Sequential therapy with belimumab followed by rituximab in Sjögren's syndrome associated with B-cell lymphoproliferation and overexp[r]ession of BAFF: Evidence for long-term efficacy. Clin Exp Rheumatol. 2014 ; 32: 490-494